PharmFormulator launches ophthalmic formulation database

PharmFormulator LLC has launched a subscription platform that gives researchers and healthcare professionals searchable estimates of inactive ingredients in ophthalmic drug products. The company says the tool is designed to improve formulation transparency, speed early-stage research and support competitive analysis.

Why it matters: - Ophthalmic formulation data is often incomplete in public labeling, making early-stage research and product comparison harder. - PharmFormulator aims to fill that gap with searchable estimates that could help scientists, pharmacists and others evaluate products faster. - The platform may reduce trial-and-error work in formulation research and lower development time and cost.

What happened: - PharmFormulator LLC announced the launch of PharmFormulator™, a subscription-based data platform for ophthalmic drug product formulation estimates. - The platform is built for researchers, pharmaceutical scientists, pharmacists and medical professionals. - PharmFormulator.com provides access to more than 1,200 U.S. ophthalmic drug-product records. - The database includes label-derived information, non-validated analytical composition estimates and public patent research references.

The details: - The platform offers quantitative estimated inactive ingredient concentrations derived from regulatory filings, patents, literature and analytical reconstructions. - Users can search by excipient name or function, pH range, osmolality, brand name, manufacturer, selected NDC-related records and FDA application number. - The service supports side-by-side comparisons of branded and generic ophthalmic products. - Source-linked documentation is included to show where the formulation data comes from. - The interface is designed to help users filter for specific formulation criteria, such as products containing a viscosity agent and preservative within a defined pH and osmolality range. - Alan L. Weiner, Ph.D., managing partner and CEO, said the platform is intended to give scientists structured data that goes beyond labeling. - Weiner said the listed formulas are not validated by analytical testing and are based on approximated data from patents and other public sources. - The company says the platform uses AI-developed tools for regular database updates and future website expansions.

Between the lines: - PharmFormulator is positioning itself as a research and competitive-intelligence tool rather than a manufacturing or clinical resource. - The product targets a wide audience, from formulation scientists and generic developers to attorneys, executives, investors and the general public. - That broad positioning suggests the company sees value not just in research speed, but also in market analysis and patent landscape work. - The emphasis on source links and estimated concentrations reflects a niche between public labeling and fully validated lab analysis.

What's next: - PharmFormulator is offering individual and multi-seat subscription tiers. - The company offers a 3-month option for users who want no long-term commitment. - Annual subscriptions are priced at a substantial discount to the 3-month rate. - Enterprise plans are configured for SSO/SCIM access. - The company says the platform is built for ongoing database updates and future capability expansions.

The bottom line: - PharmFormulator is betting that better visibility into ophthalmic inactive ingredients can speed up research, sharpen competitive analysis and make formulation work more efficient.